Punch & Associates Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-4,247
Closed -$218K 184
2023
Q4
$218K Hold
4,247
0.01% 203
2023
Q3
$246K Buy
4,247
+1,047
+33% +$64.2K 0.02% 191
2023
Q2
$205K Hold
3,200
0.01% 205
2023
Q1
$222K Hold
3,200
0.01% 193
2022
Q4
$230K Hold
3,200
0.01% 198
2022
Q3
$227K Hold
3,200
0.02% 200
2022
Q2
$246K Sell
3,200
-56
-2% -$4.26K 0.02% 203
2022
Q1
$238K Buy
3,256
+56
+2% +$3.76K 0.01% 205
2021
Q4
$200K Buy
+3,200
New +$188K 0.01% 216
2021
Q3
Sell
-3,200
Closed -$214K 242
2021
Q2
$214K Hold
3,200
0.01% 219
2021
Q1
$202K Buy
+3,200
New +$199K 0.01% 223

Other funds holding BMY

Punch & Associates Investment Management's BMY Position: Q1 2024 in Review

Punch & Associates Investment Management sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 4,247 shares — an estimated $218K sold.

Punch & Associates Investment Management first reported a position in BMY in Q1 2021 and held it in 11 quarters. The position peaked at $246K in Q3 2023. 2,332 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

  • Punch & Associates Investment Management reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
  • Punch & Associates Investment Management sold 4,247 Bristol-Myers Squibb shares in Q1 2024, an estimated $218K.
  • Punch & Associates Investment Management first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 11 quarters.
  • Punch & Associates Investment Management's Bristol-Myers Squibb position peaked at $246K in Q3 2023.
  • 2,332 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Punch & Associates Investment Management's 13F filing for Q1 2024, filed 15 May 2024.